Charles Zhou
Stock Analyst at UBS
(1.35)
# 3,471
Out of 4,947 analysts
10
Total ratings
57.14%
Success rate
-5.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $174.25 | -21.95% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $14.36 | +11.42% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $11.89 | +26.16% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.59 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.50 | +3,633.33% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.57 | +2,829.94% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.67 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $174.25
Upside: -21.95%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $14.36
Upside: +11.42%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $11.89
Upside: +26.16%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.50
Upside: +3,633.33%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.57
Upside: +2,829.94%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.67
Upside: -